Search company, investor...

Bio Control Medical

biocontrol-medical.com

Stage

Corporate Minority | Alive

Total Raised

$70M

Last Raised

$70M | 13 yrs ago

About Bio Control Medical

Bio Control Medical offers implantable devices for the treatment of incontinence and congestive heart failure.

Headquarters Location

Yehud, 56217,

Israel

+972-3-632-2126

Missing: Bio Control Medical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Bio Control Medical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Bio Control Medical Patents

Bio Control Medical has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/26/2012

12/9/2014

Vacuum tubes, Implants (medicine), Neurotechnology, Neuroprosthetics, Electrotherapy

Grant

Application Date

10/26/2012

Grant Date

12/9/2014

Title

Related Topics

Vacuum tubes, Implants (medicine), Neurotechnology, Neuroprosthetics, Electrotherapy

Status

Grant

Latest Bio Control Medical News

Global Vagus Nerve Stimulation Market 2020:Share, Application, Future Growth,Covid-19 Impact Analysis,Global Trends,Top Manufactures and Forecast Report 2027 ||LivaNova Plc, Boston Scientific, Aleva Neurotherapeutics, Bio Control Medical, Bioness

Dec 7, 2020

Data Bridge Market research released a new market study on Vagus nerve stimulation with 100+ market data Tables, Pie Chart, Graphs & Figures spread through Pages and easy to understand detailed analysis In Vagus nerve stimulation research report also directs the manufacturer about planning of advertising and sales promotion efforts and makes it more effective. The report consists of all the detailed profiles for the Vagus nerve stimulation major manufacturers and importers who are influe...

Bio Control Medical Frequently Asked Questions (FAQ)

  • Where is Bio Control Medical's headquarters?

    Bio Control Medical's headquarters is located at Yehud.

  • What is Bio Control Medical's latest funding round?

    Bio Control Medical's latest funding round is Corporate Minority.

  • How much did Bio Control Medical raise?

    Bio Control Medical raised a total of $70M.

  • Who are the investors of Bio Control Medical?

    Investors of Bio Control Medical include Medtronic, Pitango Venture Capital, Clal Biotechnology Industries and DFJ Tamir Fishman Ventures.

  • Who are Bio Control Medical's competitors?

    Competitors of Bio Control Medical include NeuroPace, Ancora Heart, TherOx, Atria Medical, CardioKinetix, CircuLite, MiCardia, Paracor Medical, Viacor, Advanced Bionics and 13 more.

Compare Bio Control Medical to Competitors

C
CoRepair

CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.

C
Chase Medical

Chase Medical is developing medical technology for treating congestive heart failure. Chase Medical is developing a device called the Mannequin which aims to help the heart maintain its shape while going through reconstruction of the left ventricle.

V
Viacor

Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of congestive heart failure.

C
Cardiac Power

Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

C
CardioKinetix

CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.